Agendia N.V.

Illumina Partners With Agendia to Expand Genomic Testing in Breast Cancer Care

Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing and to bring improved insights to patients with breast cancer globally
Press Release

SAN DIEGO, January 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology.

Subscribe to Agendia N.V.